RGD Reference Report - Valproic acid prevents penile fibrosis and erectile dysfunction in cavernous nerve-injured rats. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

Valproic acid prevents penile fibrosis and erectile dysfunction in cavernous nerve-injured rats.

Authors: Hannan, JL  Kutlu, O  Stopak, BL  Liu, X  Castiglione, F  Hedlund, P  Burnett, AL  Bivalacqua, TJ 
Citation: Hannan JL, etal., J Sex Med. 2014 Jun;11(6):1442-51. doi: 10.1111/jsm.12522. Epub 2014 Mar 18.
RGD ID: 9590194
Pubmed: PMID:24636283   (View Abstract at PubMed)
PMCID: PMC4048646   (View Article at PubMed Central)
DOI: DOI:10.1111/jsm.12522   (Journal Full-text)

INTRODUCTION: Bilateral cavernous nerve injury (BCNI) causes profound penile changes such as apoptosis and fibrosis leading to erectile dysfunction (ED). Histone deacetylase (HDAC) has been implicated in chronic fibrotic diseases. AIMS: This study will characterize the molecular changes in penile HDAC after BCNI and determine if HDAC inhibition can prevent BCNI-induced ED and penile fibrosis. METHODS: Five groups of rats (8-10 weeks, n = 10/group) were utilized: (i) sham; (ii and iii) BCNI 14 and 30 days following injury; and (iv and v) BCNI treated with HDAC inhibitor valproic acid (VPA 250 mg/kg; 14 and 30 days). All groups underwent cavernous nerve stimulation (CNS) to determine intracavernosal pressure (ICP). Penile HDAC3, HDAC4, fibronectin, and transforming growth factor-beta1 (TGF-beta1) protein expression (Western blot) were assessed. Trichrome staining and the fractional area of fibrosis were determined in penes from each group. Cavernous smooth muscle content was assessed by immunofluorescence to alpha smooth muscle actin (alpha-SMA) antibodies. MAIN OUTCOME MEASURES: We measured ICP; HDAC3, HDAC4, fibronectin, and TGF-beta1 protein expression; penile fibrosis; penile alpha-SMA content. RESULTS: There was a voltage-dependent decline (P < 0.05) in ICP to CNS 14 and 30 days after BCNI. Penile HDAC3, HDAC4, and fibronectin were significantly increased (P < 0.05) 14 days after BCNI. There was a slight increase in TGF-beta1 protein expression after BCNI. Histological analysis showed increased (P < 0.05) corporal fibrosis after BCNI at both time points. VPA treatment decreased (P < 0.05) penile HDAC3, HDAC4, and fibronectin protein expression as well as corporal fibrosis. There was no change in penile alpha-SMA between all groups. Furthermore, VPA-treated BCNI rats had improved erectile responses to CNS (P < 0.05). CONCLUSION: HDAC-induced pathological signaling in response to BCNI contributes to penile vascular dysfunction. Pharmacological inhibition of HDAC prevents penile fibrosis, normalizes fibronectin expression, and preserves erectile function. The HDAC pathway may represent a suitable target in preventing the progression of ED occurring post-radical prostatectomy.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
HDAC3HumanFibrosis  ISOHdac3 (Rattus norvegicus)protein:increased expression:penis:RGD 
HDAC4HumanFibrosis  ISOHdac4 (Rattus norvegicus)protein:increased expression:penis:RGD 
Hdac3MouseFibrosis  ISOHdac3 (Rattus norvegicus)protein:increased expression:penis:RGD 
Hdac3RatFibrosis  IEP protein:increased expression:penis:RGD 
Hdac4RatFibrosis  IEP protein:increased expression:penis:RGD 
Hdac4MouseFibrosis  ISOHdac4 (Rattus norvegicus)protein:increased expression:penis:RGD 
HDAC3Humanimpotence  ISOHdac3 (Rattus norvegicus)protein:increased expression:penis:RGD 
HDAC4Humanimpotence  IEP protein:increased expression:penis:RGD 
Hdac3Ratimpotence  IEP protein:increased expression:penis:RGD 
Hdac3Mouseimpotence  ISOHdac3 (Rattus norvegicus)protein:increased expression:penis:RGD 
Hdac4Ratimpotence  ISOHDAC4 (Homo sapiens)protein:increased expression:penis:RGD 
Hdac4Mouseimpotence  ISOHDAC4 (Homo sapiens)protein:increased expression:penis:RGD 

Objects Annotated

Genes (Rattus norvegicus)
Hdac3  (histone deacetylase 3)
Hdac4  (histone deacetylase 4)

Genes (Mus musculus)
Hdac3  (histone deacetylase 3)
Hdac4  (histone deacetylase 4)

Genes (Homo sapiens)
HDAC3  (histone deacetylase 3)
HDAC4  (histone deacetylase 4)


Additional Information